Nifty Pharma crashes nearly 2%; Cipla, Dr Reddy's among top Nifty losers after Trump's tariff plan

The Nifty Pharma index experienced a significant downturn, falling nearly 2% following the announcement of former President Donald Trump's tariff plan. This plan, unveiled recently, targets imported generic medicines, proposing a substantial increase in tariffs. The new tariffs will see a rise to 100% by August 2028, sparking concerns across the pharmaceutical sector and impacting investor sentiment. Among the hardest hit were major pharmaceutical companies Cipla and Dr Reddy's, both of which saw their shares decline, contributing to the overall dip in the Nifty Pharma index. Analysts attribute the market's reaction to fears of increased costs for generic drug imports, which could potentially affect the profitability of these companies. The proposed tariffs are expected to disrupt the supply chain and escalate the prices of essential medicines in the U.S. market. Industry experts are urging stakeholders to brace for potential challenges ahead, as the full implications of the tariff plan remain uncertain. In the wake of this announcement, there is growing anticipation around how pharmaceutical firms will strategize to mitigate the impact of heightened tariffs. Meanwhile, investors are closely monitoring the situation, seeking clarity on future trade policies and their potential ramifications on the global pharmaceutical landscape.

— Authored by Next24 Live